CClinicalTrials.gg
TerminatedNCT03343158Updated Feb 5, 2021

Orphans and Vulnerable Children Risk Screening Tool Research Study (Zimbabwe)

An observational study in Orphans, Children, Adolescents, Vulnerable Children, Adolescents and Community-based, sponsored by Elizabeth Glaser Pediatric AIDS Foundation. Terminated at 1 site in Zimbabwe. Open to participants aged 2 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-05.

Sponsored by Elizabeth Glaser Pediatric AIDS Foundation · Observational

Why this study was terminated
Significantly more resources would have been necessary to complete the study.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
2,260
Ages
2 Years to 18 Years
Sex
All
01

Study summary

Investigators propose to assess the sensitivity, specificity, positive and negative predictive value of an HIV Risk Screening Tool in identifying the risk of being HIV-infected among Orphans and Vulnerable Children (OVC) aged 2-18 years in a community setting.

Read the detailed description

In the first phase of the study, investigators will identify an optimal set of screening questions with acceptable sensitivity and false positive rate, based on the draft 11-question pilot tool. Using the identified questions, investigators will develop a composite screening tool and determine criteria that should be used for identifying children for testing with minimally acceptable sensitivity and false positive rates. In the second phase of the study, investigators will select optimal questions to create a composite screening tool and validate it in a similar study population. Investigators anticipate the accuracy of the tool will be much improved compared to the individual questions. Investigators will also assess the usability of the HIV Risk Screening Tool as measured by the time taken to administer the tool, and perceptions of its ease and simplicity.

02

Conditions studied

  • Orphans, Children, Adolescents
  • Vulnerable Children, Adolescents
  • Community-based
03

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

OVC aged 2-18 years, living in households which are registered on a database developed by World Education Institute, a Non-Government Organization which provides services for orphans and vulnerable children in the community

Inclusion criteria

  • Children/adolescents ages 2 up to 18 years living in a household and enrolled in WEI/Zimbabwe and/or partners program;
  • Children/adolescents ages 2 up to 18 years with HIV status unknown, or who tested negative three or more months ago;
  • Children/adolescents ages 2 up to 18 years who are healthy or ill (unless they are ill enough to require immediate hospitalization).

Exclusion criteria

Exclusion Criteria:

  • Children/adolescents aged 2 up to 18 years tested HIV positive
  • Children/adolescents ages 2 up to 18 years who require immediate hospitalization;
  • Children/adolescents ages 2 up to 18 years who refuse/are refused participation.
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
2,260 participants (actual)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Phase 1: Validity of various questions in predicting the probability of HIV among OVC (Screening tool)

    Sensitivity and specificity of eleven questions in predicting HIV among OVC

    Time frame: Four weeks

  2. Phase 2: Validation of combined questions in predicting HIV among OVC (Validating Screen tool)

    Validation of combined questions assessed from Phase 1 in predicting HIV among OVC

    Time frame: Six weeks

Secondary outcomes

  1. Usability of screening tool

    CHWs who participate in the screening will be invited to participate in a short survey, offered in either Shona or English (depending on participant choice), on the ease, simplicity, and usability of the screening tool, as well as perceptions of the process

    Time frame: Two weeks

06

Study locations

1 site
  • EGPAF Zimbabwe
    Harare, Zimbabwe
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03343158
Lead sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Collaborators
JSI Research & Training Institute, Inc., Biomedical Research and Training Institute, Zimbabwe, United States Agency for International Development (USAID), World Education, Inc.
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Oct 17, 2017
Primary completion
Feb 28, 2018
Completion
Mar 31, 2018
Last update
Feb 5, 2021

Study contacts

Agnes Mahomva, MD
principal investigator · Elizabeth Glaser Pediatric AIDS Foundation
Godfrey Woelk, PhD
principal investigator · Elizabeth Glaser Pediatric AIDS Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion